ViewRay Announces Pricing of Public Offering of Common Stock
ViewRay, Inc. (Nasdaq: VRAY) announced a public offering of 12,500,000 shares of common stock priced at $5.60 per share, aiming to raise $70 million in gross proceeds. The offering will close on or about November 19, 2021, subject to closing conditions. ViewRay plans to utilize the proceeds for general corporate purposes, including working capital, capital expenditures, and ongoing R&D. The underwriting team includes Piper Sandler and Stifel, among others. There is also a 30-day option for underwriters to purchase an additional 1,875,000 shares.
- Raising $70 million in gross proceeds can improve liquidity for future projects.
- Funds will support continued research and development, potentially enhancing future product offerings.
- Issuing new shares may lead to shareholder dilution.
- The stock price may be pressured due to the increased share count from the offering.
CLEVELAND, Nov. 16, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the MRIdian, which combines MRI and external-beam radiation therapy to simultaneously image and treat cancer patients, today announced the pricing of an underwritten public offering of 12,500,000 shares of common stock at a price to the public of
ViewRay intends to use the net proceeds from the offering for general corporate purposes, including working capital, capital expenditures, continued research and development and commercial expenses.
Piper Sandler and Stifel are acting as the joint book-running managers for the offering. Guggenheim Securities is also acting as a book-running manager for the offering. B. Riley Securities and BTIG are acting as co-managers for the offering.
The offering is expected to close on or about November 19, 2021, subject to satisfaction of customary closing conditions.
A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission ("SEC") and automatically became effective upon filing. This offering is being made solely by means of a prospectus supplement and accompanying prospectus included in the registration statement. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Alternatively, copies of the final prospectus supplement, when available, and the accompanying prospectus may be obtained by contacting Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@psc.com, or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
Except for historical information, certain statements in this press release, including statements regarding the completion and the anticipated use of proceeds of the public offering, as well as ViewRay's expectations regarding the completion of its proposed public offering, are forward-looking in nature and are subject to risks, uncertainties and assumptions about us, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of closing conditions related to the public offering. Such forward-looking statements involve substantial risks and uncertainties that relate to future events and the actual results could differ significantly from those expressed or implied by the forward-looking statements. Any forward-looking statements are based on ViewRay's current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. ViewRay makes no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, please refer to the "Risk Factors" sections in ViewRay's preliminary prospectus supplement filed with the SEC on November 16, 2021, including the documents incorporated by reference therein, its Annual Report on Form 10-K filed with the SEC on March 5, 2021, its Quarterly Reports on Form 10-Q filed with the SEC on May 7, 2021, August 6, 2021, and November 5, 2021 and certain of its other reports filed with the SEC.
View original content:https://www.prnewswire.com/news-releases/viewray-announces-pricing-of-public-offering-of-common-stock-301426306.html
SOURCE ViewRay, Inc.
FAQ
What is the price of ViewRay's public offering of common stock?
How much money does ViewRay aim to raise from the offering?
When is the expected closing date for ViewRay's stock offering?
What are the intended uses of the proceeds from ViewRay's offering?
Who are the underwriters for ViewRay's public offering?
